Navigation Links
Angiotech announces positive results from Bio-Seal(TM) clinical study
Date:3/9/2009

VANCOUVER, March 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced positive clinical study results for its Bio-Seal(TM) Lung Biopsy Tract Plug System at the Society of Interventional Radiologists Annual Scientific Meeting in San Diego, CA. The trial assessed the safety and efficacy of Bio-Seal in patients undergoing lung biopsy procedures and demonstrated a statistically significant clinical benefit in the group receiving BioSeal.

"We are extremely pleased that the Bio-Seal treatment arm hit the primary end point of clinical success," said Dr. William Hunter, President and CEO of Angiotech. "These results indicate that Bio-Seal improves the existing technology used to diagnose lung cancer by significantly reducing the rates of pneumothorax."

The purpose of this clinical study was to assess the safety and efficacy of an expanding hydrogel plug in reducing pneumothorax rates associated with CT-guided lung biopsy. The prospective, randomized, controlled clinical study enrolled and randomized 339 investigational patients at 15 different investigational sites. Inspiratory upright chest x-rays were performed at 30 to 60 minutes, 24 hours and 30 days after treatment. The Bio-Seal treatment arm hit the primary end point of clinical success, absence of pneumothorax at each time period. Based on the per-protocol population, clinical success rate was 85% using Bio-Seal and 69% in the control group. This difference was statistically significant (p=0.002). Although not powered for statistical analysis, positive trends were also observed for Bio-Seal subjects as compared to the control group in various secondary endpoints, including fewer Bio-Seal subjects admitted to the hospital for pneumothoraces (9.4% vs. 13.6%), fewer chest tubes placements in Bio-Seal patients (3.5% vs. 10.7%), and fewer additional chest x-r
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor ... 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... Pa. , July 30, 2015  Discovery ... that it has received the second $1.0M tranche ... Innovation Research (SBIR) grant valued at up to ... company,s aerosolized KL4 surfactant as a potential medical ... injury.  Discovery Labs was awarded an initial $1.0 ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... - 11, ... 2008 San Jose, California, AUBURN ... Online on-demand software for the medical manufacturing,enterprise, is exhibiting at ... Jose McEnery Conference Center, San Jose,California., (Logo: http://www.newscom.com/cgi-bin/prnh/20070627/CLW071LOGO ...
... Update on the Regulatory Strategy for Belinostat in PTCL, ... announced that a positive reply from the FDA was ... III trial for belinostat,in PTCL (Peripheral T-Celle Lymphoma). This ... to begin in Q4 2008. In June Fast Track,designation ...
... 5 /PRNewswire-FirstCall/ - Ondine Biopharma,Corporation (TSX: OBP; ... products, today announced that a poster entitled,"Photodisinfection ... be,presented by Company representatives at the American ... AAP meeting is being,held at the Washington ...
Cached Biology Technology:Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference 2Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 2Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 3Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 4Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 5Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontology's 94th Annual Meeting 2
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... Why do people become physically weaker as they age? ... reverse this process, breaking the link between increasing age and ... in the Journal of Clinical Endocrinology & Metabolism , ... that answers to both those questions can be found in ...
... five-year follow up study in Bangladesh finds that women are ... families and even their neighbors. Using the simple sari ... cholera, but reduces the incidence of disease in neighboring households ... appear in the inaugural issue of mBio , the ...
... a team of researchers led by Jeffrey Peng, assistant ... Notre Dame, is using Nuclear Magnetic Resonance (NMR), to ... flexibility of drugs and their targets. The research, ... Chemical Society, contributes to the growing attention given toward ...
Cached Biology News:Muscle loss in elderly linked to blood vessels' failure to dilate 2Sari cloth a simple sustainable protector from cholera 2Nuclear magnetic resonance aids in drug design 2
... Maximize the value of your microarray ... offer the support you need from ... the most up to date methods. ... the Gene Expression Profiling Service or ...
... fast, easy to use, reproducible and reliable ... 15 times faster and 5 times more ... ,The VoluPAC tubes enable the determination of ... cell suspension, resulting in absolute data correlating ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
... This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (Z71,517-4) or ... Material: cap polystyrene (expanded surface, easy ...
Biology Products: